Emergent BioSolutions Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Emergent BioSolutions Inc. on June 7, 2012, covering an event dated June 1, 2012. The report details a material definitive agreement entered into by the Company's wholly-owned subsidiary, Emergent BioDefense Operations Lansing LLC ("EBOL").
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial figure disclosed is the additional funding associated with the contract modification.
- Additional Contract Funding: Up to $8.4 million.
Material Changes
On June 1, 2012, EBOL entered into a contract modification with the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services. Key changes include:
- New Study Requirement: EBOL must conduct a non-interference study to support the Post-Exposure Prophylaxis ("PEP") indication for BioThrax (Anthrax Vaccine Adsorbed).
- Contract Extension: The base period of performance is extended from September 25, 2007, through March 31, 2016.
- Deliverables Update: The Milestone Table and Deliverables have been modified to incorporate the new study and extended timeline.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, general outlook commentary, or a discussion of risks and contingencies beyond the specific terms of the contract modification. The unusual item reported is the specific agreement to conduct the non-interference study for the BioThrax PEP indication.
Investor Verification Checklist
- Verify the status and timeline of the non-interference study for BioThrax PEP indication.
- Confirm the recognition of the $8.4 million in additional funding in future financial reports.
- Monitor the impact of the extended contract period (through March 31, 2016) on future revenue streams.
- Review subsequent filings for any changes to the Milestone Table or Deliverables.